SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 3
    Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 4
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with RBV for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
  • 5
    Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 6
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
  • 7
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
  • 8
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 9
    Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy R, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011; 364: 2405-2416.
  • 10
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of the phase 3 ILLUMINATE Study. HEPATOLOGY 2010; 52( Suppl 1):Abstract LB-2.
  • 11
    Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Ther Adv Gastroenterol 2010; 3: 191-202.
  • 12
    Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009; 50: 184-194.
  • 13
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
  • 14
    Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. HEPATOLOGY 2007; 46: 640-648.
  • 15
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278.
  • 16
    Afdhal NH, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, et al. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior nonresponse to PEGIFN/RBV: week 24 results. J Hepatol 2006; 44( Suppl 2): S19.
  • 17
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
  • 18
    Gane EJ, Roberts SK, Stedman PW, Angus B, Ritchie R, Elston D, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
  • 19
    Di Bisceglie AM, Nelson DR, Gane E, Alves K, Koziel MJ, De Souza TL, et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: ZENITH study interim results. J Hepatol 2011; 54( Suppl 1): S540.
  • 20
    Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, et al. Mechanistic characterization of GS-9190 (TEGOBUVIR), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2011; 55: 4196-4203.
  • 21
    Bavisotto L, Wang CC, Jacobson IM, Marcellin P, Zeuzem S, Lawitz EJ, et al. Antiviral, pharmacokinetic, and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. HEPATOLOGY 2007; 46( Suppl 1): 255A.
  • 22
    Lawitz EJ, Marbury TC, Vince BD, Grunenberg N, Rodriguez-Torres M, De Micco MP, et al. Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. J Hepatol 2010; 52( Suppl 1): S466-S467.
  • 23
    Lawitz E, Jacobson I, Godofsky E, Foster GR, Flisiak R, Bennett M, et al. A phase 2B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG-RBV for chronic genotype 1 HCV infection. J Hepatol 2011; 54( Suppl 1): S181.
  • 24
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 25
    Manns MP, Bourliere M, Benhamou Y, Stanislas P, Bonacini M, Trepo C, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-1122.
  • 26
    Sane R, Podila L, Mathur K, Mease M, Taub Q, Huang M, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54( Suppl 1): S488.
  • 27
    Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
  • 28
    Zoulim F, Haem J, Ahmed SS, Chossegros P, Habersetzer F, Chevallier M, et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998; 5: 193-198.
  • 29
    Zeuzem S, Asselah T, Angus P, Zarski J-P, Larrey D, Müllhaupt B, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial. HEPATOLOGY 2010; 52( Suppl 1):Abstract LB-7.
  • 30
    Lok A, Gardiner D, Lawitz E, Martorell C, Everson G, Ghalib R, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011; 54( Suppl 1): 1356.
  • 31
    Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst M, Clemons D, Mcnair L, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the Nuclear study). J Hepatol 2011; 54( Suppl 1):Abstract LB-1370.